FSD Pharma Inc. has made so much progress. FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) retained an independent advisor to evaluate more broadly its principal drug compound, ultramicronized palmitoylethanolamide (PEA), or FSD201, in order to evaluate its current commercial viability.